Castle Biosciences (CSTL) CCO Juvenal Tobin Sells Shares

What Happened
Juvenal Tobin, Chief Commercial Officer of Castle Biosciences (CSTL), sold a total of 6,577 shares in open‑market transactions on Sept. 29–30, 2026. The sale comprised 5,543 shares at a reported weighted‑average price of $35.50 (total ≈ $196,765) and 1,034 shares at a reported weighted‑average price of $34.20 (total ≈ $35,363), for combined proceeds of about $232,128. These were sales (not purchases) and therefore are often routine liquidity events rather than explicit bullish signals.

Key Details

• Transaction dates: 2026-09-29 (5,543 shares @ $35.50 WA) and 2026-09-30 (1,034 shares @ $34.20 WA).
• Reported proceeds: ~$196,765 and ~$35,363, respectively; combined ≈ $232,128 (USD).
• Price ranges: 9/29 trades executed between $35.010 and $35.935 (weighted average reported as $35.50); 9/30 trades between $34.090 and $34.525 (weighted average reported as $34.20). The filer offered to provide detailed per‑trade prices on request.
• Plan / footnote: The 9/29–9/30 sales were made pursuant to a Rule 10b5‑1 trading plan adopted May 28, 2026 (pre‑arranged plan).
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: Form filed 2026-10-01; the filing does not indicate it was late.

Context
A 10b5‑1 plan lets insiders sell shares according to a pre‑set schedule or formula and can reduce the likelihood that the sale reflects the insider’s current view of the company. For retail investors, routine insider sales under 10b5‑1 plans are common and generally less informative than purchases; they often reflect diversification or personal liquidity needs rather than a change in confidence. The filer’s offer to supply trade‑level details means exact execution prices and quantities per trade can be obtained from the SEC staff or issuer on request.